|
|
||||||||
National Research Council of Canada, Institute for Biological Sciences, Ottawa, Ontario, Canada
Archaeal isopranoid glycerolipid vesicles (archaeosomes) serve as strong adjuvants for cell-mediated responses to entrapped Ag. We analyzed the processing pathway of OVA entrapped in archaeosomes composed of Methanobrevibacter smithii lipids, high in archaetidylserine (OVA-archaeosomes). In vitro, OVA-archaeosomes stimulated spleen cells from OVA-TCR-transgenic mice, D011.10 (CD4+ cells expressing OVA323339 TCR) or OT1 (>90% CD8+ OVA257264 cells), indicating both MHC class I and II presentations. In vivo, when naive (Thy1.2+) CFSE-labeled OT1 cells were transferred into OVA-archaeosome-immunized Thy 1.1+ recipient mice, there was profound accumulation and cycling of donor-specific cells, and differentiation of H-2KbOva257264 CD8+ T cells into CD44highCD62Llow effectors. Both macrophages and dendritic cells (DCs) efficiently cross-presented OVA-archaeosomes on MHC class I. Blocking phagocytosis by phosphatidylserine-specific receptor agonists strongly inhibited MHC class I presentation of OVA-archaeosomes, whereas blocking mannose receptors or FcRs lacked effect, indicating specific recognition of the archaetidylserine head group of M. smithii lipids by APCs. In addition, inhibitors of endosomal acidification blocked MHC class I processing of OVA-archaeosomes, whereas endosomal protease inhibitors lacked effect, suggesting acidification-dependent phagosome-to-cytosol diversion. Proteasomal inhibitors blocked OVA-archaeosome MHC class I presentation, confirming cytosolic processing. Both in vitro and in vivo, OVA-archaeosome MHC class I presentation required TAP. Ag-free archaeosomes also activated DC costimulation and cytokine production, without overt inflammation. Phosphatidylserine-specific receptor-mediated endocytosis is a mechanism of apoptotic cell clearance and DCs cross-present Ags sampled from apoptotic cells. Our results reveal the novel ability of archaeosomes to exploit this mechanism for cytosolic MHC class I Ag processing, and provide an effective particulate vaccination strategy.
This article has been cited by other articles:
![]() |
G D. Sprott, C. J Dicaire, J.-P. Cote, and D. M Whitfield Adjuvant potential of archaeal synthetic glycolipid mimetics critically depends on the glyco head group structure Glycobiology, July 1, 2008; 18(7): 559 - 565. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. V. Popovic, R. Sandhoff, T. P. Sijmonsma, S. Kaden, R. Jennemann, E. Kiss, E. Tone, F. Autschbach, N. Platt, E. Malle, et al. Sulfated Glycosphingolipid as Mediator of Phagocytosis: SM4s Enhances Apoptotic Cell Clearance and Modulates Macrophage Activity J. Immunol., November 15, 2007; 179(10): 6770 - 6782. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Krishnan, K. Gurnani, C. J. Dicaire, H. van Faassen, A. Zafer, C. J. Kirschning, S. Sad, and G. D. Sprott Rapid Clonal Expansion and Prolonged Maintenance of Memory CD8+ T Cells of the Effector (CD44highCD62Llow) and Central (CD44highCD62Lhigh) Phenotype by an Archaeosome Adjuvant Independent of TLR2 J. Immunol., February 15, 2007; 178(4): 2396 - 2406. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |